Drugs / DEVEXTINETUG
DEVEXTINETUG
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05027451 | Oct 2021 → Mar 2022 | — | InterveXion Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01603147 | Apr 2012 → Jul 2013 | substance abuse | InterveXion Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03336866 | May 2018 → Nov 2020 | amphetamine abuse, methamphetamine dependence | InterveXion Therapeutics, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05034874 | Jun 2022 → Sep 2023 | amphetamine abuse, methamphetamine dependence | InterveXion Therapeutics, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04715230 | Jun 2021 → Oct 2022 | methamphetamine-induced psychosis | InterveXion Therapeutics, LLC | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEVEXTINETUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095323 ↗ |
| Known as | ch-mAb7f9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01603147 ↗ |
| Known as | IXT-m200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05034874 ↗ |
| Modality | Monoclonal antibody | “anti-(+)-methamphetamine monoclonal antibody” PMID 25742165 ↗ Mar 2015 |
| Route | Intravenous | “Ch-mAb7F9 will be administered intravenously (IV)” NCT01603147 ↗ |